Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Toulouse
Clinical trial register · France

Clinical Trials in Toulouse, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9697 matching records held by the registry are in this view. Synced 26 Oct 2026, 03:20 UTC
9697
Studies in scope
all four open statuses
6025
Recruiting now
open to new participants
1033
Lead sponsors
across recruiting studies
Top sites
Paris 68 Marseille 36 Bordeaux 35 Montpellier 32 Lille 31
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University Hospital, Toulouse170 AstraZeneca32 Merck Sharp & Dohme LLC32 Novartis Pharmaceuticals30 AbbVie26 Clear sponsor filter
Site location
Paris68 Marseille36 Bordeaux35 Montpellier32 Lille31
All 73 locations
Target enrolment
to

Trials with a site in Toulouse

30 of 9697 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
NCT07498335Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy
DrugAtrasentan
Novartis Pharmaceuticals
Phase 3
28
Bron, Nantes, Toulouse
2026-08-06
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Caen, Créteil, Lille, Marseille, Nantes, Paris, Rennes, Toulouse
2026-06-03
Recruiting
Novartis Pharmaceuticals
Phase 1
194
Marseille, Toulouse
2026-05-28
Active, closed
Novartis Pharmaceuticals
Phase 3
5,700
Bron, Chambray-lès-Tours, Compiègne, Grenoble, Le Coudray, Nantes, Paris, Toulouse
2026-05-11
Recruiting
Novartis Pharmaceuticals
Phase 2
210
Bordeaux, Brest, Créteil, Nice, Reims, Rouen, Toulouse
2026-03-09
Recruiting
Novartis Pharmaceuticals
Phase 2
140
Angers, Bron, Dijon, Montpellier, Paris, Toulouse, Tours
2025-10-09
Active, closed
Novartis Pharmaceuticals
Phase 2
97
Toulouse, Paris
2025-08-07
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
Bron, Clichy, Montpellier, Nantes, Pessac, Toulouse
2025-05-30
Active, closed
Novartis Pharmaceuticals
Phase 3
565
Nice, Brest, La Rochelle, Lyon, Reims, Rouen, Toulouse
2025-03-20
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Bordeaux, Nice, Paris, Strasbourg, Toulouse
2025-02-07
Active, closed
Novartis Pharmaceuticals
Phase 2
201
Dijon, Le Mans, Lille, Montpellier, Paris, Rennes, Strasbourg, Toulouse
2024-10-09
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Bordeaux, Clermont-Ferrand, Marseille, Montpellier, Nantes, Paris, Strasbourg, Toulouse
2024-09-04
Active, closed
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
DrugsIptacopan·Rituximab
Novartis Pharmaceuticals
Phase 2
84
Angers, Brest, Dijon, Marseille, Paris, Toulouse
2024-08-05
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Montpellier, Paris, Toulouse
2024-05-21
Recruiting
Novartis Pharmaceuticals
Phase 3
50
Bordeaux, Paris, Rouen, Toulouse, Tours
2024-02-28
Active, closed
Novartis Pharmaceuticals
Phase 3
362
Grenoble, Montpellier, Nantes, Paris, Pierre-Bénite, Rouen, Toulouse
2023-12-07
Recruiting
Novartis Pharmaceuticals
Phase 3
106
Marseille, Montpellier, Paris, Rennes, Toulouse
2023-10-02
Active, closed
Novartis Pharmaceuticals
Phase 2
41
Toulouse
2023-08-16
Active, closed
Novartis Pharmaceuticals
Phase 1
123
Bordeaux, Marseille, Toulouse
2023-06-27
Active, closed
Novartis Pharmaceuticals
Phase 3
288
Montpellier, Paris, Toulouse, Tours
2023-04-21
Active, closed
Novartis Pharmaceuticals
Phase 2
33
Toulouse
2023-02-28
Active, closed
Novartis Pharmaceuticals
Phase 1
38
Lille, Paris, Toulouse
2023-02-23
Recruiting
Novartis Pharmaceuticals
Phase 3
195
Besançon, Toulouse
2023-02-10
Active, closed
Novartis Pharmaceuticals
Phase 3
20
Bron, Garches, Strasbourg, Toulouse
2022-12-19
Active, closed
Novartis Pharmaceuticals
Phase 3
452
Besançon, Bordeaux, Grenoble, Lyon, Marseille, Poitiers, Toulouse, Vandœuvre-lès-Nancy
2022-07-14
Active, closed
Novartis Pharmaceuticals
Phase 3
610
Paris, Pessac, Poitiers, Toulouse
2022-07-08
Active, closed
Novartis Pharmaceuticals
Phase 3
208
Lille, Nantes, Nice, Paris, Toulouse
2021-07-27
Active, closed
Novartis Pharmaceuticals
Phase 2
134
Lille, Marseille, Paris, Pierre-Bénite, Toulouse, Villejuif
2020-10-30
Recruiting
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT03955445C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
225
Montpellier, Paris, Toulouse
2019-10-03
Active, closed
Novartis Pharmaceuticals
Phase 3
240
Bordeaux, Le Kremlin-Bicêtre, Marseille, Montpellier, Toulouse
2013-07-26
Rows per page Showing 1–30 of 30
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 October 2026. https://priyalifescience.com/clinical-trials-france/city/toulouse

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,697 studies in total at the last sync on 26 Oct 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 30 of those studies with a site in Toulouse that also match the filters currently applied.

How many clinical trials are recruiting in Toulouse?

11 of the 30 studies on this page are recruiting new participants as of the 26 Oct 2026, 03:20 UTC sync. A further 0 have not yet opened recruitment, 19 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Toulouse), 30 studies
PhaseStudiesRecruitingShare
Phase 318860%
Phase 29230%
Phase 13110%

Most active sponsors

Lead sponsors with the most studies (Toulouse)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals3011
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.